Literature DB >> 11844686

Synthesis of a magnosalin derivative, 4-(3,4,5-trimethoxyphenyl)-6-(2,4,5-trimethoxyphenyl)-2-diethylaminopyrimidine, and the anti-angiogenic and anti-rheumatic effect on mice by oral administration.

Katsunao Tanaka1, Yasuo Konno, Yasushi Kuraishi, Ikuko Kimura, Takashi Suzuki, Mamoru Kiniwa.   

Abstract

We describe here the synthesis and the anti-angiogenic and anti-rheumatic activities of 4-(3,4,5-trimethoxyphenyl)-6-(2,4,5-trimethoxyphenyl)-2-diethylaminopyrimidine (TAS-202), a derivative of magnosalin, which is a natural product isolated from Flos magnoliae. TAS-202 inhibited the proliferation of vascular endothelial cells more potently than magnosalin, and when given orally it inhibited basic fibroblast growth factor (bFGF)-induced angiogenesis and collagen-induced arthritis in mice. This magnosalin derivative with anti-angiogenic effects is a candidate for the treatment of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844686     DOI: 10.1016/s0960-894x(01)00810-1

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Antitumor activity of bis-indole derivatives.

Authors:  Aldo Andreani; Silvia Burnelli; Massimiliano Granaiola; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Lucilla Varoli; Laura Landi; Cecilia Prata; Michael V Berridge; Carole Grasso; Heinz-Herbert Fiebig; Gerhard Kelter; Angelika M Burger; Mark W Kunkel
Journal:  J Med Chem       Date:  2008-07-04       Impact factor: 7.446

2.  Discovery of novel sulfonated small molecules that inhibit vascular tube formation.

Authors:  Karthik Raman; Rajesh Karuturi; Vimal P Swarup; Umesh R Desai; Balagurunathan Kuberan
Journal:  Bioorg Med Chem Lett       Date:  2012-04-16       Impact factor: 2.823

3.  Magnoliae flos Downregulated Lipopolysaccharide-Induced Inflammatory Responses via NF-κB/ERK-JNK MAPK/STAT3 Pathways.

Authors:  Tae-Young Gil; Bo-Ram Jin; Yun-Yeop Cha; Hyo-Jin An
Journal:  Mediators Inflamm       Date:  2022-06-26       Impact factor: 4.529

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.